Literature DB >> 17989306

Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin.

Nicole Exner1, Bettina Treske, Dominik Paquet, Kira Holmström, Carola Schiesling, Suzana Gispert, Iria Carballo-Carbajal, Daniela Berg, Hans-Hermann Hoepken, Thomas Gasser, Rejko Krüger, Konstanze F Winklhofer, Frank Vogel, Andreas S Reichert, Georg Auburger, Philipp J Kahle, Bettina Schmid, Christian Haass.   

Abstract

Degeneration of dopaminergic neurons in the substantia nigra is characteristic for Parkinson's disease (PD), the second most common neurodegenerative disorder. Mitochondrial dysfunction is believed to contribute to the etiology of PD. Although most cases are sporadic, recent evidence points to a number of genes involved in familial variants of PD. Among them, a loss-of-function of phosphatase and tensin homolog-induced kinase 1 (PINK1; PARK6) is associated with rare cases of autosomal recessive parkinsonism. In HeLa cells, RNA interference-mediated downregulation of PINK1 results in abnormal mitochondrial morphology and altered membrane potential. Morphological changes of mitochondria can be rescued by expression of wild-type PINK1 but not by PD-associated PINK1 mutants. Moreover, primary cells derived from patients with two different PINK1 mutants showed a similar defect in mitochondrial morphology. Human parkin but not PD-associated mutants could rescue mitochondrial pathology in human cells like wild-type PINK1. Our results may therefore suggest that PINK1 deficiency in humans results in mitochondrial abnormalities associated with cellular stress, a pathological phenotype, which can be ameliorated by enhanced expression of parkin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17989306      PMCID: PMC6673250          DOI: 10.1523/JNEUROSCI.0719-07.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  30 in total

Review 1.  Mitochondrial filaments and clusters as intracellular power-transmitting cables.

Authors:  V P Skulachev
Journal:  Trends Biochem Sci       Date:  2001-01       Impact factor: 13.807

2.  Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease.

Authors:  Ekaterina Rogaeva; Janel Johnson; Anthony E Lang; Cindy Gulick; Katrina Gwinn-Hardy; Toshitaka Kawarai; Christine Sato; Angharad Morgan; John Werner; Robert Nussbaum; Agnes Petit; Michael S Okun; Aideen McInerney; Ronald Mandel; Justus L Groen; Hubert H Fernandez; Ron Postuma; Kelly D Foote; Shabnam Salehi-Rad; Yan Liang; Sharon Reimsnider; Anurag Tandon; John Hardy; Peter St George-Hyslop; Andrew B Singleton
Journal:  Arch Neurol       Date:  2004-12

Review 3.  Modelling neurodegenerative diseases in Drosophila: a fruitful approach?

Authors:  Miratul M K Muqit; Mel B Feany
Journal:  Nat Rev Neurosci       Date:  2002-03       Impact factor: 34.870

4.  Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants.

Authors:  Jessica C Greene; Alexander J Whitworth; Isabella Kuo; Laurie A Andrews; Mel B Feany; Leo J Pallanck
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

5.  Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.

Authors:  Vincenzo Bonifati; Patrizia Rizzu; Marijke J van Baren; Onno Schaap; Guido J Breedveld; Elmar Krieger; Marieke C J Dekker; Ferdinando Squitieri; Pablo Ibanez; Marijke Joosse; Jeroen W van Dongen; Nicola Vanacore; John C van Swieten; Alexis Brice; Giuseppe Meco; Cornelia M van Duijn; Ben A Oostra; Peter Heutink
Journal:  Science       Date:  2002-11-21       Impact factor: 47.728

Review 6.  How does parkin ligate ubiquitin to Parkinson's disease?

Authors:  Philipp J Kahle; Christian Haass
Journal:  EMBO Rep       Date:  2004-07       Impact factor: 8.807

7.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

Review 8.  Mitochondria and dopamine: new insights into recessive parkinsonism.

Authors:  Jie Shen; Mark R Cookson
Journal:  Neuron       Date:  2004-08-05       Impact factor: 17.173

9.  Hereditary early-onset Parkinson's disease caused by mutations in PINK1.

Authors:  Enza Maria Valente; Patrick M Abou-Sleiman; Viviana Caputo; Miratul M K Muqit; Kirsten Harvey; Suzana Gispert; Zeeshan Ali; Domenico Del Turco; Anna Rita Bentivoglio; Daniel G Healy; Alberto Albanese; Robert Nussbaum; Rafael González-Maldonado; Thomas Deller; Sergio Salvi; Pietro Cortelli; William P Gilks; David S Latchman; Robert J Harvey; Bruno Dallapiccola; Georg Auburger; Nicholas W Wood
Journal:  Science       Date:  2004-04-15       Impact factor: 47.728

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  242 in total

Review 1.  The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease.

Authors:  Victor S Van Laar; Sarah B Berman
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

2.  Hyperexcitable substantia nigra dopamine neurons in PINK1- and HtrA2/Omi-deficient mice.

Authors:  Matthew W Bishop; Subhojit Chakraborty; Gillian A C Matthews; Antonios Dougalis; Nicholas W Wood; Richard Festenstein; Mark A Ungless
Journal:  J Neurophysiol       Date:  2010-10-06       Impact factor: 2.714

Review 3.  Recent advances in the genetics of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Genomics Hum Genet       Date:  2011       Impact factor: 8.929

4.  Mitochondrially localized PKA reverses mitochondrial pathology and dysfunction in a cellular model of Parkinson's disease.

Authors:  R K Dagda; A M Gusdon; I Pien; S Strack; S Green; C Li; B Van Houten; S J Cherra; C T Chu
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

5.  PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility.

Authors:  Xinnan Wang; Dominic Winter; Ghazaleh Ashrafi; Julia Schlehe; Yao Liang Wong; Dennis Selkoe; Sarah Rice; Judith Steen; Matthew J LaVoie; Thomas L Schwarz
Journal:  Cell       Date:  2011-11-11       Impact factor: 41.582

Review 6.  Cell signaling and mitochondrial dynamics: Implications for neuronal function and neurodegenerative disease.

Authors:  Theodore J Wilson; Andrew M Slupe; Stefan Strack
Journal:  Neurobiol Dis       Date:  2012-01-24       Impact factor: 5.996

Review 7.  Regulation of Parkin E3 ubiquitin ligase activity.

Authors:  Helen Walden; R Julio Martinez-Torres
Journal:  Cell Mol Life Sci       Date:  2012-04-19       Impact factor: 9.261

8.  Lysosomal activity regulates Caenorhabditis elegans mitochondrial dynamics through vitamin B12 metabolism.

Authors:  Wei Wei; Gary Ruvkun
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-31       Impact factor: 11.205

Review 9.  Mitochondrial morphology-emerging role in bioenergetics.

Authors:  Chad A Galloway; Hakjoo Lee; Yisang Yoon
Journal:  Free Radic Biol Med       Date:  2012-09-29       Impact factor: 7.376

Review 10.  Posttranslational modification and quality control.

Authors:  Xuejun Wang; J Scott Pattison; Huabo Su
Journal:  Circ Res       Date:  2013-01-18       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.